Open label extension studies and patient selection biases

Journal of Evaluation in Clinical Practice

Volumn 14, Issue 1, 2008, Pages 141-144

  Hemming, Karla ^a   Hutton, Jane L ^a   Maguire, Melissa J ^b   Marson, Anthony G ^b  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Anti epileptic drugs (AEDs); Missing at random (MAR); Open label extension studies; Patient selection biases

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; GABAPENTIN; PLACEBO;

ANALYTIC METHOD; ASSAY; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; OPEN LABEL EXTENSION STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SEIZURE;

DEFIBRILLATORS; ETHICS, CLINICAL; ETHICS, RESEARCH; HUMANS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SELECTION BIAS;

EID: 38349070361     PISSN: 13561294     EISSN: 13652753     Source Type: Journal    
DOI: 10.1111/j.1365-2753.2007.00821.x     Document Type: Review

References (8)

1. Betts, T., Waegemans, T. Crawford, P. (2000) A multicenre, double-blind, randomised, parellel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure, 9, 80 87.
2. Taylor, G. J. Wainwright, P. (2005) Open label extension studies: research or marketing. British Medical Journal, 331, 572 574.
3. Pocock, S. J. Elbourne, D. R. (2000) Randomised trials or observational tribulations? New England Journal of Medicine, 342, 1907 1909.
4. Marson, A. G., Kadir, Z. A., Hutton, J. L. Chadwick, D. W. (2000) The new anti-epileptic drugs: a systematic review of thier efficacy and tolerability. Epilepsia, 38, 859 880.
5. The US Gabapentin study Group (1993) Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind placebo-controlled, parallel-Group study. Neurology, 11, 2292 2298.
6. The US Gabapentin study Group (1994) The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug resistent partial epilepsy. Epilepsy Research, 18, 67 73.
7. Little, R. J. A. Rubin, D. B. (2002) Statistical Analysis of Missing Data, 2nd edn. Hoboken, NJ:John Wiley.
8. Hubbard, W. K 1998) International conference on harmonisation: guidance on statistical principals for clinical trials. Federal Register, 63 (179 49583 49598.